Regorafenib in combination with temozolomide with or without radiotherapy in patients with newly diagnosed MGMT-Methylated, IDH wild-type glioblastoma. A phase I dose-finding study (REGOMA-2).

2024-514424-16-00 Protocol REGOMA-2 Human pharmacology (Phase I) - Other Ended

Start 4 Jul 2022 · End 22 Dec 2025 · Status Ended · 1 EU/EEA countries · 2 sites · Protocol REGOMA-2

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 36
Countries 1
Sites 2

MGMT-Methylated, IDH wild-type glioblastoma

Key facts

Sponsor
Istituto Oncologico Veneto
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
4 Jul 2022 → 22 Dec 2025
Decision date (initial)
2025-01-27
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-514424-16-00
EudraCT number
2021-001604-15
ClinicalTrials.gov
NCT06095375

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

MGMT-Methylated, IDH wild-type glioblastoma

VersionLevelCodeTermSystem organ class
20.0 PT 10018336 Glioblastoma 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Istituto Oncologico Veneto

Sponsor organisation
Istituto Oncologico Veneto
Address
Via Gattamelata 64
City
Padova
Postcode
35128
Country
Italy

Scientific contact point

Organisation
Istituto Oncologico Veneto
Contact name
Gian Luca De Salvo

Public contact point

Organisation
Istituto Oncologico Veneto
Contact name
Gian Luca De Salvo

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Ended 36 2
Rest of world 0

Investigational sites

Italy

2 sites · Ended
Istituto Oncologico Veneto
UOC Oncologia 1, Via Gattamelata 64, 35128, Padova
Humanitas Mirasole S.p.A.
Unità di Sviluppo Farmaci Innovativi nei Tumori Solidi e in Neuro-Oncologia, Via Alessandro Manzoni 56, 20089, Rozzano

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Italy 2022-07-04 2025-12-22 2022-07-04 2024-08-21

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-12-10 Italy Acceptable
2025-01-22
2025-01-27
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-12-05 Italy Acceptable
2025-01-22
2025-12-05